메뉴 건너뛰기




Volumn 37, Issue 5, 2015, Pages 353-357

Comparison of aldosterone synthesis in adrenal cells, effect of various AT1 receptor blockers with or without atrial natriuretic peptide

Author keywords

Adrenocortical cell; Aldosterone; Atrial natriuretic peptide; Bifunctional angiotensin II type 1 receptor blocker; Molecule specific effects

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; AZILSARTAN; GUANINE NUCLEOTIDE BINDING PROTEIN; IRBESARTAN; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; OLMESARTAN; TELMISARTAN;

EID: 84944057089     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2014.987391     Document Type: Review
Times cited : (18)

References (19)
  • 1
    • 79952564650 scopus 로고    scopus 로고
    • Review: Angiotensin II type 1 receptor blockers: Class effects versus molecular effects
    • Miura S, Karnik SS, Saku K. Review: Angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst 2011;12:1-7.
    • (2011) J Renin Angiotensin Aldosterone Syst , vol.12 , pp. 1-7
    • Miura, S.1    Karnik, S.S.2    Saku, K.3
  • 2
    • 84898739822 scopus 로고    scopus 로고
    • Japanese society of hypertension committee for guidelines for the management of hypertension. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2014)
    • Shimamoto K, Ando K, Fujita T, et al. Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37:253-392.
    • (2014) Hypertens Res , vol.37 , pp. 253-392
    • Shimamoto, K.1    Ando, K.2    Fujita, T.3
  • 3
    • 70349980161 scopus 로고    scopus 로고
    • Next generation multifunctional angiotensin receptor blockers
    • Kurtz TW, Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res 2009;32:826-34.
    • (2009) Hypertens Res , vol.32 , pp. 826-834
    • Kurtz, T.W.1    Klein, U.2
  • 4
    • 84867583095 scopus 로고    scopus 로고
    • TRC120038, a novel dual AT(1)/ET(A) receptor blocker for control of hypertension, diabetic nephropathy, and cardiomyopathy in ob-ZSF1 rats
    • Mohanan A, Gupta R, Dubey A, et al. TRC120038, a novel dual AT(1)/ET(A) receptor blocker for control of hypertension, diabetic nephropathy, and cardiomyopathy in ob-ZSF1 rats. Int J Hypertens 2011:751513.
    • (2011) Int J Hypertens , pp. 751513
    • Mohanan, A.1    Gupta, R.2    Dubey, A.3
  • 5
    • 33646078807 scopus 로고    scopus 로고
    • New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: Design, synthesis, and biopharmacological properties
    • Breschi MC, Calderone V, Digiacomo M, et al. New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties. J Med Chem 2006;49:2628-39.
    • (2006) J Med Chem , vol.49 , pp. 2628-2639
    • Breschi, M.C.1    Calderone, V.2    Digiacomo, M.3
  • 6
    • 84889823658 scopus 로고    scopus 로고
    • New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension
    • Monge M, Lorthioir A, Bobrie G, Azizi M. New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension. J Renin Angiotensin Aldosterone Syst 2013;14:285-9.
    • (2013) J Renin Angiotensin Aldosterone Syst , vol.14 , pp. 285-289
    • Monge, M.1    Lorthioir, A.2    Bobrie, G.3    Azizi, M.4
  • 7
    • 84897030265 scopus 로고    scopus 로고
    • Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: A randomized, double-blind, placebocontrolled study
    • Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: A randomized, double-blind, placebocontrolled study. Hypertension 2014;63:698-705.
    • (2014) Hypertension , vol.63 , pp. 698-705
    • Kario, K.1    Sun, N.2    Chiang, F.T.3
  • 8
    • 84901983713 scopus 로고    scopus 로고
    • Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: An analysis of the paramount trial
    • Jhund PS, Claggett B, Packer M, et al. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: An analysis of the PARAMOUNT trial. Eur J Heart Fail 2014;16:671-7.
    • (2014) Eur J Heart Fail , vol.16 , pp. 671-677
    • Jhund, P.S.1    Claggett, B.2    Packer, M.3
  • 9
    • 0021926025 scopus 로고
    • Inhibition of aldosterone biosynthesis by atriopeptins in rat adrenal cells
    • Campbell WB, Currie MG, Needleman P. Inhibition of aldosterone biosynthesis by atriopeptins in rat adrenal cells. Circ Res 1985;57: 113-18.
    • (1985) Circ Res , vol.57 , pp. 113-118
    • Campbell, W.B.1    Currie, M.G.2    Needleman, P.3
  • 10
    • 0031753505 scopus 로고    scopus 로고
    • Functionally active catalytic domain is essential for guanylyl cyclase-linked receptor mediated inhibition of human aldosterone synthesis
    • Olson LJ, Ho BY, Cashdollar LW, Drewett JG. Functionally active catalytic domain is essential for guanylyl cyclase-linked receptor mediated inhibition of human aldosterone synthesis. Mol Pharmacol 1998;54:761-9.
    • (1998) Mol Pharmacol , vol.54 , pp. 761-769
    • Olson, L.J.1    Ho, B.Y.2    Cashdollar, L.W.3    Drewett, J.G.4
  • 11
    • 84864274671 scopus 로고    scopus 로고
    • Eplerenone is not superior to older and less expensive aldosterone antagonists
    • Chatterjee S, Moeller C, Shah N, et al. Eplerenone is not superior to older and less expensive aldosterone antagonists. Am J Med 2012; 125:817-25.
    • (2012) Am J Med , vol.125 , pp. 817-825
    • Chatterjee, S.1    Moeller, C.2    Shah, N.3
  • 12
    • 77957699101 scopus 로고    scopus 로고
    • A small difference in the molecular structure of angiotensin II receptor blockers induces AT1 receptor-dependent and -independent beneficial effects
    • Fujino M, Miura S, Kiya Y, et al. A small difference in the molecular structure of angiotensin II receptor blockers induces AT1 receptor-dependent and -independent beneficial effects. Hypertens Res 2010;33:1044-52.
    • (2010) Hypertens Res , vol.33 , pp. 1044-1052
    • Fujino, M.1    Miura, S.2    Kiya, Y.3
  • 13
    • 84892540245 scopus 로고    scopus 로고
    • Reassessment of the unique mode of binding between angiotensin II type 1 receptor and their blockers
    • Miura S, Nakao N, Hanzawa H, et al. Reassessment of the unique mode of binding between angiotensin II type 1 receptor and their blockers. PLoS One 2013;8:e79914.
    • (2013) PLoS One , vol.8 , pp. e79914
    • Miura, S.1    Nakao, N.2    Hanzawa, H.3
  • 14
    • 84873548926 scopus 로고    scopus 로고
    • Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan
    • Miura S, Okabe A, Matsuo Y, et al. Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertens Res 2013;36:134-9.
    • (2013) Hypertens Res , vol.36 , pp. 134-139
    • Miura, S.1    Okabe, A.2    Matsuo, Y.3
  • 15
    • 79951979674 scopus 로고    scopus 로고
    • In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies
    • Ojima M, Igata H, Tanaka M, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011;336: 801-8.
    • (2011) J Pharmacol Exp Ther , vol.336 , pp. 801-808
    • Ojima, M.1    Igata, H.2    Tanaka, M.3
  • 16
    • 33745842894 scopus 로고    scopus 로고
    • Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor
    • Miura S, Fujino M, Hanzawa H, et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem 2006;281:19288-95.
    • (2006) J Biol Chem , vol.281 , pp. 19288-19295
    • Miura, S.1    Fujino, M.2    Hanzawa, H.3
  • 17
    • 43249125270 scopus 로고    scopus 로고
    • Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart
    • Tokudome T, Kishimoto I, Horio T, et al. Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation 2008;117: 2329-39.
    • (2008) Circulation , vol.117 , pp. 2329-2339
    • Tokudome, T.1    Kishimoto, I.2    Horio, T.3
  • 18
    • 0031748816 scopus 로고    scopus 로고
    • Dose-related antihypertensive effects of irbesartan in patients with mild-tomoderate hypertension
    • Pool JL, Guthrie RM, Littlejohn III TW, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-tomoderate hypertension. Am J Hypertens 1998;11:462-70.
    • (1998) Am J Hypertens , vol.11 , pp. 462-470
    • Pool, J.L.1    Guthrie, R.M.2    Littlejohn, T.W.3
  • 19
    • 34548163060 scopus 로고    scopus 로고
    • The incidence and implications of aldosterone breakthrough
    • Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007;3: 486-92.
    • (2007) Nat Clin Pract Nephrol , vol.3 , pp. 486-492
    • Bomback, A.S.1    Klemmer, P.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.